Skip to main content
. 2020 Jun 29;7(5):2042–2050. doi: 10.1002/ehf2.12834

Figure 1.

Figure 1

Initial GP behaviour (n = 500) in the presence of hyperkalaemia (level according to each physician) in patients treated with ACEi/ARBs (in the absence of details regarding medical history) or in patients with HF and/or CKD treated with MRA. *Refer to open‐ended Question 2.5: In the presence of hyperkalaemia at a threshold defined in Question 1.2 to Question 1.4, what is your approach in a patient under renin–angiotensin system inhibitor (ACEi/ARB) treatment? (several answers were possible). **Refer to open‐ended Question 2.3: In a patient with HF and CKD, under aldosterone antagonist (MRA) (Aldactone© spironolactone; or Inspra©, eplerenone) treatment, what is your approach in the presence of hyperkalaemia at a threshold defined in (Question 1.2 to Question 1.4)? (several answers were possible). Legend: HF, heart failure; CKD, chronic kidney disease; ACEi, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; ED or hospitalization, emergency department or hospitalization; GP, general practitioner; MRA, mineralocorticoid receptor antagonist.